NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free NCNA Stock Alerts $0.37 +0.02 (+5.76%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.31▼$0.3850-Day Range$0.28▼$0.4252-Week Range$0.23▼$1.75Volume1.25 million shsAverage Volume4.52 million shsMarket Capitalization$19.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NuCana alerts: Email Address NuCana MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,262.4% Upside$5.00 Price TargetShort InterestHealthy0.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.97 out of 5 starsMedical Sector419th out of 947 stocksPharmaceutical Preparations Industry193rd out of 431 stocks 3.5 Analyst's Opinion Consensus RatingNuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, NuCana has a forecasted upside of 1,262.4% from its current price of $0.37.Amount of Analyst CoverageNuCana has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.21% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently increased by 293.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NCNA. Previous Next 2.9 News and Social Media Coverage News SentimentNuCana has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for NuCana this week, compared to 0 articles on an average week.Search Interest6 people have searched for NCNA on MarketBeat in the last 30 days. MarketBeat Follows8 people have added NuCana to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.54% of the stock of NuCana is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NuCana are expected to grow in the coming year, from ($0.61) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r About NuCana Stock (NASDAQ:NCNA)NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Read More NCNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NCNA Stock News HeadlinesMarch 14, 2024 | finance.yahoo.comNuCana (NASDAQ:NCNA) Will Have To Spend Its Cash WiselyMarch 13, 2024 | msn.comWhy NuCana Stock Is Up TodayMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 13, 2024 | msn.comWhy Is Surgepays (SURG) Stock Down 27% Today?March 13, 2024 | investorplace.comWhy Is NuCana (NCNA) Stock Up 102% Today?February 27, 2024 | finanznachrichten.deNuCana plc: NuCana to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 27, 2024 | finance.yahoo.comNuCana to Present at TD Cowen’s 44th Annual Health Care ConferenceFebruary 27, 2024 | globenewswire.comNuCana to Present at TD Cowen's 44th Annual Health Care ConferenceMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 26, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday TradingFebruary 23, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%February 6, 2024 | finanznachrichten.deNuCana plc: NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finance.yahoo.comNuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Wednesday TradingJanuary 3, 2024 | seekingalpha.comNuCana: Potential Turnaround In 2024 But RiskyDecember 29, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Higher FridayDecember 26, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Advance TuesdayDecember 22, 2023 | benzinga.comNuCana Stock (NASDAQ:NCNA) Dividends: History, Yield and DatesNovember 23, 2023 | benzinga.comNuCana Stock (NASDAQ:NCNA), Analyst Ratings, Price Targets, PredictionsNovember 16, 2023 | finanznachrichten.deNuCana plc: NuCana Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 16, 2023 | finance.yahoo.comNuCana Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 10, 2023 | finance.yahoo.comNuCana Announces Listing Transfer to Nasdaq Capital MarketNovember 1, 2023 | finance.yahoo.comNuCana to Participate in the Truist Securities 2023 BioPharma SymposiumOctober 16, 2023 | finance.yahoo.comNuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023October 10, 2023 | msn.comWhy Is NuCana (NCNA) Stock Down Today?October 5, 2023 | msn.comNuCana plc - ADR (NCNA) Price Target Increased by 15.39% to 5.10September 28, 2023 | finance.yahoo.comBears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' NowSee More Headlines Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/17/2021Today3/19/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NCNA CUSIPN/A CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,262.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.25% Return on Assets-75.52% Debt Debt-to-Equity RatioN/A Current Ratio2.57 Quick Ratio2.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book0.40Miscellaneous Outstanding Shares52,290,000Free Float35,978,000Market Cap$19.19 million OptionableNot Optionable Beta0.96 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Hugh Stephen Griffith (Age 56)Founder, CEO & Executive Director Comp: $1.29MMr. Donald Munoz (Age 55)Chief Financial Officer Mr. David Harrison (Age 65)Head of Translational Medicine Prof. Christopher B. Wood FRCS (Age 78)M.D., Ph.D., Chief Medical Officer Comp: $104.77kMs. Theresa BruceSenior Vice President of Clinical OperationsMs. Elisabeth OelmannSenior Vice President of Medical & Clinical DevelopmentDr. Jeffrey D. Bloss F.A.C.O.G. (Age 67)M.D., Chief Medical Officer Martin QuinnCompany SecretaryMore ExecutivesKey CompetitorsLandos BiopharmaNASDAQ:LABPKALA BIONASDAQ:KALAYumanity TherapeuticsNASDAQ:YMTXLipocineNASDAQ:LPCNGalectoNASDAQ:GLTOView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 146,083 shares on 2/15/2024Ownership: 0.279%View All Institutional Transactions NCNA Stock Analysis - Frequently Asked Questions Should I buy or sell NuCana stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NCNA shares. View NCNA analyst ratings or view top-rated stocks. What is NuCana's stock price target for 2024? 2 brokerages have issued 12-month price targets for NuCana's shares. Their NCNA share price targets range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 1,262.4% from the stock's current price. View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts. How have NCNA shares performed in 2024? NuCana's stock was trading at $0.2958 at the start of the year. Since then, NCNA shares have increased by 24.1% and is now trading at $0.3670. View the best growth stocks for 2024 here. Are investors shorting NuCana? NuCana saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 91,300 shares, an increase of 293.5% from the February 14th total of 23,200 shares. Based on an average trading volume of 154,400 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.2% of the shares of the company are short sold. View NuCana's Short Interest. When is NuCana's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our NCNA earnings forecast. How were NuCana's earnings last quarter? NuCana plc (NASDAQ:NCNA) released its quarterly earnings data on Wednesday, November, 17th. The company reported ($15.00) EPS for the quarter, topping the consensus estimate of ($18.50) by $3.50. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH). When did NuCana IPO? (NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. Who are NuCana's major shareholders? NuCana's stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.28%). How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NCNA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.